Figure 1
![An external file that holds a picture, illustration, etc.
Object name is ajtr0009-3758-f1.jpg An external file that holds a picture, illustration, etc.
Object name is ajtr0009-3758-f1.jpg](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575190/bin/ajtr0009-3758-f1.jpg)
Summary of mechanism of action of widely used small molecule DMARDs. MTX is a folic acid antagonist (acts by inhibiting dihydro-folate reductase, DHFR). Leflunomide inhibits pyrimidine synthesis in T lymphocytes (acts by inhibiting dihydroorotate dehydrogenase, DOD). Sulfasalazine exerts immune-suppressive effect by pooling adenosine. All three drugs inhibit activation of T cell and antigen presenting cells (APC), and consequent augmented release of pro-inflammatory interleukins and TNF. By these mechanisms, these DMARDs suppress activation of target cells in the joint and mitigate progression of RA.